Netherlands Pharmaceuticals and Healthcare Report Q3 2012

Published : May 2012
No. of Pages : 80

Price:

BMI View: While the Netherlands is a low risk market from the point of view of multinational drugmakers, the country’s modest per capita expenditure on pharmaceuticals relative to other Western Europe countries remains an issue. A further challenge facing drugmakers is cost-containment, which can only intensify as the Netherlands enters a phase of slower economic growth.
Headline Expenditure Projections 􀂃 Pharmaceuticals: EUR6.70bn (US$9.31bn) in 2011 to EUR6.54bn (US$8.44bn) in 2012; -2.4% decline in local currency terms and -9.4% decline in US dollar terms.
􀂃 Healthcare: EUR63.32bn (US$88.02bn) in 2011 to EUR65.09bn (US$83.96bn) in 2012; +2.8% growth in local currency terms and -4.60% growth in US dollar terms.
􀂃 Medical devices: EUR11.41bn (US$15.86bn) in 2011 to EUR11.77bn (US$15.18bn) in 2012; 3.2% growth in local currency terms and -4.2% in US dollar terms
􀂃 Business Environment Rating: The Netherlands’ composite score in our latest Pharmaceutical Risk/Reward Ratings (RRRs) matrix for Western Europe is unchanged from the previous quarter. The figure of 64.2 out of the maximum 100 ranks it seventh out of the 10 markets in the matrix. Despite a developed healthcare market, the Netherlands’ overall ranking continues to be propped up by its favourable risk variable, with the rewards negatively impacted by costcontainment, in combination with patent expirations.
Key Trends And Developments • In April 2012, a Chinese traditional medicine was authorized for sale in a European market for the first time – Di'ao Xin Xue Kang, a well-known herbal medicine produced by the Chengdu based Di'ao Group, received marketing authorization from the Medicines Evaluation Board of the Netherlands, making it the first Chinese traditional drug to be identified as a therapeutic medicine in the European Union.
BMI Economic View: The Dutch economy's exposure to the eurozone sovereign debt crisis continues to weigh heavily on economic activity and confidence. As a result, our weaker outlook for domestic demand means we now forecast the economy to contract by 0.3% in 2012, from our previous 0.4% real GDP growth forecast. Weak longer-term economic activity in the eurozone is also set to drag on the Netherland's growth trajectory and we forecast economic growth to average a weak 1.1% to 2016..
BMI Political View: The stability of Netherlands’ Prime Minister Mark Rutte's minority government is likely to come under increased pressure in 2012, as the negotiations over Dutch involvement in eurozone bailout packages expose rifts between the coalition parties. In particular, with the far-right Party For Freedom gaining momentum, a coalition breakdown cannot be precluded, which could potentially stall some of the government’s fiscal austerity measures.

Executive Summary . 5
SWOT Analysis 6
Netherlands Pharmaceuticals And Healthcare Industry SWOT . 6
Netherlands Political SWOT .. 7
Netherlands Economic SWOT 7
Netherlands Business Environment SWOT. 8
Pharmaceutical Risk/Reward Ratings ... 9
Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q312 11
Rewards ... 11
Risks . 12
The Netherlands – Market Summary ... 13
Regulatory Regime 14
Regulatory Developments 15
Intellectual Property Regime ... 15
Pricing And Reimbursement Regime 16
Industry Developments . 19
Epidemiology ... 19
Healthcare Sector 20
Healthcare Funding . 21
Health Insurance.. 21
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 . 22
Healthcare Insurance Developments ... 23
Research And Development Sector .. 24
Clinical Trials .. 27
Medical Devices Industry . 27
Medical Devices Industry Developments . 27
Industry Forecast Scenario .. 29
Overall Market Forecast .. 29
Table: Pharmaceutical Sales Indicators 2008-2016 30
Healthcare Market Forecast 31
Table: Healthcare Expenditure Indicators 2008-2016 32
Table: Healthcare Governmental Indicators 2008-2016. 33
Table: Healthcare Private Indicators 2008-2016 33
Key Growth Factors – Macroeconomic 34
NETHERLANDS – ECONOMIC ACTIVITY 37
Prescription Drug Market Forecast . 38
Table: Prescription Drug Sales Indicators 2008-2016 38
Patented Drug Market Forecast .. 39
Table: Patented Drug Market Indicators 2008-2016 ... 40
Generic Drug Market Forecast . 41
Table: Generic Drug Sales Indicators 2008-2016 ... 42
OTC Medicine Market Forecast .. 43
Table: OTC Medicine Sales Indicators 2008-2016 .. 45
Pharmaceutical Trade Forecast ... 46
Table: Exports and Imports Indicators 2008-2016 .. 46
Medical Devices Market Forecast 48
Table: Medical Devices Sales Indicators 2008-2016 ... 49
Other Healthcare Data 50
Key Risks To BMI’s Forecast Scenario 50
Competitive Landscape 51
Pharmaceutical Industry .. 51
Company Activities .. 51
Pharmaceutical Wholesale Sector 53
Pharmaceutical Retail Sector .. 54
Wholesale And Retail Sector Developments . 54
Company Profiles .. 55
Local Manufacturers . 55
DSM . 55
Qiagen . 57
Pharming Group .. 59
Multinational Manufacturers 61
Merck & Co . 61
Pfizer 63
GlaxoSmithKline .. 65
Sanofi ... 67
Novartis ... 69
Demographic Data . 70
NETHERLANDS – Population By Age Group . 71
NETHERLANDS – Population By Age Group . 71
NETHERLANDS – Key Population Ratios ... 72
NETHERLANDS – Rural and Urban Population . 73
Glossary . 74
BMI Methodology ... 76
How We Generate Our Pharmaceutical Industry Forecasts 76
Pharmaceuticals Business Environment Ratings . 77
Risk/Reward Ratings Methodology .. 77
Ratings Overview . 77
Table: Pharmaceutical Business Environment Indicators 78
Weighting . 79
Table: Weighting Of Components 79
Sources 79Table: Western Europe Pharmaceuticals Risk/Reward Ratings, Q312 . 11

Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 . 22

Table: Pharmaceutical Sales Indicators 2008-2016 . 30

Table: Healthcare Expenditure Indicators 2008-2016 . 32

Table: Healthcare Governmental Indicators 2008-2016. 33

Table: Healthcare Private Indicators 2008-2016 . 33

Table: Prescription Drug Sales Indicators 2008-2016 . 38

Table: Patented Drug Market Indicators 2008-2016 . 40

Table: Generic Drug Sales Indicators 2008-2016 . 42

Table: OTC Medicine Sales Indicators 2008-2016 . 45

Table: Exports and Imports Indicators 2008-2016 . 46

Table: Medical Devices Sales Indicators 2008-2016 . 49

Table: Pharmaceutical Business Environment Indicators . 78

Table: Weighting Of Components . 79

Netherlands Pharmaceuticals and Healthcare Report Q3 2012

Published By: Business Monitor International

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: